The successful transfer of high-potency oral solid dose drug manufacturing processes to contract development and manufacturing organizations (CDMOs) relies on clear communication and structured procedures, according to industry insights. Experts emphasize that a well-coordinated approach is essential for ensuring the seamless transition of these complex pharmaceutical operations.
Key factors identified in the process include establishing robust communication channels between all stakeholders, defining clear roles and responsibilities, and implementing comprehensive project management strategies. Additionally, attention to detail in areas such as equipment compatibility, regulatory compliance, and risk assessment plays a critical role in minimizing disruptions during the transfer. These steps aim to ensure that product quality, safety standards, and timelines are maintained throughout the transition process.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
Date: September 3, 2025
發佈留言